Broadalumab Efficacy in Axial Spondyloarthritis Save
Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).
This multicentre phase 3 trial conducted in Japan, Korea and Taiwan, randomized axSpA patients to received either subcutaneous brodalumab 210 mg (n=80) or placebo (n=79) (baseline, weeks 1 and 2, then every 2 weeks) for 16-weeks. The primary endpoint was the proportion of patients with Assessment of SpondyloArthritis International Society (ASAS) 40 response at week 16.
A total of 159 axSpA patients were treated at at week 16 the ASAS 40 response rate was:
- Broadalumab - 43.8%
- Placebo - 24.1% (p=0.018)
Broadalumab also yielded significantly better ASAS 20 response rates (67.5% vs 41.8%) and change in ASDAS-CRP (–1.322 vs –0.672). Adverse events were evenly reported between groups.
Another IL-17 inhibitor has show significant clinical benefits when given to patients with active axSpA.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.